Arvind Mehta, MD
Nephrology · Long Beach, CANPI 1518985613
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AstraZeneca at 33.4% of the total. That places this record below the midpoint for nephrology clinicians in CA, where the typical reported total is $1,018.
Across 48 payments — averaging $23.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$375
- Amgen$169
- Vifor Pharma, Inc.$133
- Akebia Therapeutics Inc$114
- Novartis$74
- Mallinckrodt Hospital Products Inc.$70
- plus $187 from 4 others
Across 1,136 payments — averaging $1736.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$1.6M
- GSK$256K
- AstraZeneca$127K
- Boehringer Ingelheim$12K
- Novo Nordisk AS$7K
- Boehringer Ingelheim International GmbH$39
What the payments were for
- Food & beverage$1,11299%
- Education$91%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 19 | $375 |
| Amgen(2 entities) | 10 | $169 |
| Vifor Pharma, Inc. | 6 | $133 |
| Akebia Therapeutics Inc | 6 | $114 |
| Novartis | 1 | $74 |
| Mallinckrodt Hospital Products Inc. | 1 | $70 |
| Ardelyx, Inc. | 1 | $67 |
| Kyowa Kirin, Inc. | 1 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Aurinia Pharma U.S., Inc. | 1 | $22 |
How this compares
$1,121 in reported general payments places this provider in the 50th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProsolParenteral Amino Acid 20% No.1 | 16 | $2,576 |
| Bisoprolol Fumarate | 11 | $330 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Long Beach
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.